Rydapt (Midostaurin) Patent Expiration, LOE Window & CMS Spending

Rydapt (Midostaurin) by Novartis: FDA Orange Book LOE 2030-12-02, 2 AB generics, $35.8M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN207997 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-12-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$35.8M
2024 Medicare Part D Spend$27.4M
2024 Medicaid Spend$8.4M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 24.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.